Allarity Therapeutics Secures CLIA For In-House Lab
Benzinga Newsdesk 3 months ago
BiotechGeneralNews
Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must be performed in a
- Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environment
- The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment
- CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity’s lead agent, stenoparib
- Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization
- Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization